EU Regulator Backs Oral Wegovy, First GLP-1 Pill in Region
The EMA's CHMP recommended approval of oral Wegovy (semaglutide 25 mg daily) on May 22 — the first oral GLP-1 pill backed for EU weight management.
May 25, 2026 · 3 min read
On the same day it recommended EU approval for a higher-dose injectable Wegovy pen, Novo Nordisk's European Medicines Agency committee backed a second product: the oral Wegovy pill. The CHMP issued a positive opinion on May 22 for Wegovy in tablet form — once-daily oral semaglutide 25 mg — making it the first oral GLP-1 receptor agonist recommended for marketing authorisation for weight management in the European Union.
What happened
The CHMP recommendation is based on the OASIS 4 trial, which tested the once-daily 25 mg oral semaglutide pill in adults with obesity or overweight who had at least one weight-related comorbidity. In that trial, participants who adhered to treatment lost a mean of 16.6% of their body weight. Approximately one in three participants achieved at least 20% body weight loss.
The oral Wegovy pill received FDA approval in the US in December 2025 and launched commercially in January 2026. The CHMP recommendation paves the way for European Commission approval — which typically follows CHMP opinions within two months — and a subsequent EU commercial launch.
One detail in the label is notable: Wegovy pill carries no drug-drug restrictions for concomitant medications. This is a meaningful contrast to Rybelsus (oral semaglutide approved for type 2 diabetes), which requires a 30-minute fasting window and restricts co-administration with other medications because of its sensitivity to gastric pH. The new Wegovy pill uses a different formulation and delivery mechanism that eliminates those constraints.
The CHMP positive opinion also incorporates the SELECT trial's cardiovascular outcome data into the proposed EU label, which demonstrated that Wegovy reduces the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and overweight or obesity. That means European prescribers and payers will see a product label that goes beyond weight management alone.
Why it matters
Two audiences stand to benefit most from an approved oral Wegovy in Europe:
Injection-averse patients. A meaningful proportion of people who might benefit from a GLP-1 therapy decline because they don't want to inject. An oral option with proven 16.6% weight loss eliminates that barrier — with efficacy that still substantially exceeds anything previously available in pill form for weight management.
Patients on multiple medications. The absence of drug-drug restrictions in the Wegovy pill label makes it easier to use in people with complex medication regimens, where Rybelsus's fasting and separation requirements were logistically difficult. The primary care setting, where polypharmacy is common, will likely benefit most from this.
The pill's 16.6% mean weight loss is meaningfully below tirzepatide's ceiling (~22.5%) and below the new injectable Wegovy 7.2 mg (20.7%). But for patients who can't or won't inject, it represents the highest-performing non-injectable option now approved.
What to watch
The European Commission decision is expected by late July 2026. Novo Nordisk's US commercial experience with oral Wegovy — including prescribing patterns and payer coverage relative to injectable Wegovy — will inform EU launch strategy. Early US data showed strong uptake among patients who had previously declined injection-based therapy, which will be the primary commercial narrative for the EU rollout.
Sources
Sources